The invention also comprises {HEAD ~ a pharmaceutical composition} comprising {TAIL ~ a first antibody} or an antigen binding fragment thereof, and a second antibody, or an antigen binding fragment thereof, wherein the first antibody is an antibody of the invention, and the second antibody is an antibody that neutralizes hCMV infection 
comprising
The invention also comprises { HEAD ~ a pharmaceutical composition } comprising { TAIL ~ a first antibody } or an antigen binding fragment thereof , and a second antibody , or an antigen binding fragment thereof , wherein the first antibody is an antibody of the invention , and the second antibody is an antibody that neutralizes hCMV infection
OTH OTH OTH OTH HEAD HEAD HEAD HEAD HEAD HEAD HEAD REL TAIL TAIL TAIL TAIL TAIL TAIL TAIL OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH